Exploration of Constructing and Applying a Risk Assessment Model for Neuromuscular Blocking Agent Dosage in Elderly Patients Undergoing General Anesthesia Based on Machine Learning

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400087246

Enrollment

Unknown

Registered

2024-07-23

Start date

2024-07-31

Completion date

Unknown

Last updated

2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

R1:Rocuronium induction dose: R1 = 0.3 mg/kg

R2:Rocuronium induction dose: R2 = 0.45mg/kg

R3:Rocuronium induction dose: R3= 0.6mg/kg

Eligibility

Sex/Gender

All

Age

60 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Age = 60 years; (2) Patients undergoing elective general anesthesia; (3) American Society of Anesthesiologists (ASA) classification I-III; (4) No gender restriction; (5) Non-emergency surgeries; (6) Obtain informed consent from patients and have them sign the informed consent form.

Exclusion criteria

Exclusion criteria: Preoperative abnormal liver function, abnormal kidney function, neuromuscular dysfunction, heart failure, arrhythmias, and coronary artery disease; intraoperative use of vasoactive drugs; patients with cognitive impairment and a history of mental illness.

Design outcomes

Primary

Measure	Time frame
Muscle strength level;Accuracy of Model;Precision of Model;Sensitivity;Specificity;Receiver Operating Characteristic Curve;Area Under the Curve;Postoperative residual neuromuscular blockade;	—

Secondary

Measure	Time frame
Perioperative complications;Blood biochemical test results;Imaging examination results;	—

Countries

China

Contacts

Public ContactBin Zhao

Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University

zbgbtj0926@gmail.com+86 139 1621 5478

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026